Evergreen Theragnostics is a contract development and manufacturing platform specializing in the development of theragnostic radiopharmaceuticals for cancer treatment. The company enhances treatment options for patients by providing tailored radiopharmaceutical solutions that improve diagnostic accuracy and therapeutic efficacy.
Funding
$63.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PHFounders
Product
Problem
Cancer treatment often lacks precision, leading to ineffective therapies and unnecessary side effects. Traditional diagnostic methods may not accurately identify the specific characteristics of a tumor, hindering the selection of the most appropriate treatment. The development and manufacturing of specialized radiopharmaceuticals for targeted cancer therapy is complex and requires specialized expertise and facilities.
Solution
Evergreen Theragnostics is a contract development and manufacturing organization (CDMO) focused on theragnostic radiopharmaceuticals, offering customized solutions for cancer treatment. They provide end-to-end services, from early-stage development and analytical testing to GMP manufacturing and regulatory support, enabling pharmaceutical companies to develop and commercialize targeted radiotherapies. By leveraging their expertise in radiochemistry and pharmaceutical development, Evergreen Theragnostics helps improve diagnostic accuracy and therapeutic efficacy, ultimately enhancing treatment options for cancer patients. Their services streamline the development process, reducing time to market and ensuring the quality and safety of radiopharmaceutical products.
Target Audience
Evergreen Theragnostics serves pharmaceutical and biotechnology companies developing novel radiopharmaceuticals for cancer diagnosis and therapy.
Features
- Radiopharmaceutical development and manufacturing services, including API synthesis, formulation development, and aseptic fill-finish.
- Analytical testing and quality control, ensuring product purity, potency, and stability.
- GMP-compliant manufacturing facilities with specialized equipment for handling radioactive materials.
- Regulatory support, including assistance with IND and NDA submissions.
- Custom radiopharmaceutical design and optimization for specific cancer targets.
- Expertise in a range of radioisotopes, including lutetium-177, actinium-225, and iodine-131.